Original scientific paper

https://doi.org/10.21860/medflum2020_237302

Concordance of estimated residual tumor size by magnetic resonance imaging and pathohistologic findings in breast cancer patients after neoadjuvant chemotherapy

Elvis Černeka ; Istarski domovi zdravlja
Petra Valković Zujić ; Klinički bolnički centar Rijeka, Klinički zavod za radiologiju
Damir Grebić ; Klinički bolnički centar Rijeka, Zavod za opću i onkološku kirurgiju
Manuela Avirović ; Klinički bolnički centar Rijeka, Klinički zavod za patologiju i citologiju
Damir Miletić ; Klinički bolnički centar Rijeka, Klinički zavod za radiologiju

Abstract

Aim: The goal of this study is to evaluate the concordance between residual tumour size measured on magnetic resonance imaging (MRI) and pathohistological findings in patients who underwent neoadjuvant chemotherapy and operative procedure, and if any pathohistological features may affect that agreement. Respondents and methods: Fifty patients with breast cancer were retrospectively evaluated. Patients who underwent neoadjuvant chemotherapy before the operative procedure, and were assessed with at least two MRI examinations, where included in this study. The primary tumour size measured by MRI was compared with pathohistological findings, which was considered as the gold standard. All differences and size correspondence were analyzed as well as the possible influence of ypT stage of tumour between the two methods. Results: The mean value of residual tumour size on MRI was 19,2 ± 17,71 mm, while on pathohistological findings it was 16,87 ± 18,29 mm. A calculated correlation coefficient between the two methods was 0.64 (p < 0.001). There was no statistically significant difference between two methods for measuring residual tumour size (p = 0.552), as well as a statistically significant influence of ypT stage on measuring, so these methods may be considered to be concordant. Conclusions: There is neither a constant nor a proportional deviation in the measurements between the two methods, so these methods can be considered concordant. Breast MRI is a reliable method for estimating residual tumour size in patients undergoing neoadjuvant chemotherapy in comparison to pathology.

Keywords

breast cancer; magnetic resonance imaging; neoadjuvant chemotherapy; residual disease

Hrčak ID:

237302

URI

https://hrcak.srce.hr/237302

Publication date:

1.6.2020.

Article data in other languages: croatian

Visits: 3.473 *